{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004478","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.956088+00:00","generated_at":"2026-05-28T02:46:14.156834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M","bullets":["Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).","LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).","LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.","2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.","Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004478","json":"https://secwatch.observer/filing/0000950170-25-004478.json","markdown":"https://secwatch.observer/filing/0000950170-25-004478.md","text":"https://secwatch.observer/filing/0000950170-25-004478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/0000950170-25-004478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/rxst-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:46:14.156834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}